Table 2 Primary composite and safety (bleeding complications) endpoints
Outcomes | Rivaroxaban (n = 362) | Dabigatran (n = 186) | Warfarin (n = 126) | P value |
|---|---|---|---|---|
DRT | 11 (3.0%) | 11 (5.9%) | 8 (6.3%) | 0.157 |
TE* | 15 (4.1%) | 16 (8.6%) | 11 (8.7%) | 0.054 |
 Ischemic strokes | 3 (0.8%) | 2 (1.1%) | 2 (1.6%) | 0.777 |
 TIA | 2 (0.6%) | 2 (1.1%) | 1 (0.8%) | 0.839 |
 SE | 10 (2.8%) | 12 (6.5%) | 8 (6.3%) | 0.073 |
Overall DRT & TE | 26 (7.2%) | 24 (12.9%) | 17 (13.5%) | 0.036* |
Hospital readmission due to cardiac causes | 12 (3.3%) | 7 (3.8%) | 6 (4.8%) | 0.760 |
Total Bleeding | 13 (3.6%) | 6 (3.2%) | 7 (5.6%) | 0.324 |
 GI bleeding | 6 (1.7%) | 2 (1.1%) | 3 (2.4%) | 0.670 |
 Hematuria | 2 (0.6%) | 2 (1.1%) | 0.0% | 0.699 |
 Operation site hemorrhage | 3 (0.8%) | 0.0% | 2 (1.6%) | 0.266 |
 Epistaxis | 0.0% | 1 (0.5%) | 0.0% | 0.652 |
 Bleeding gums | 0.0% | 1 (0.5%) | 2 (1.6%) | 0.068 |
 Skin ecchymosis | 2 (0.6%) | 0.0% | 0.0% | 0.238 |